Autophagy regulates drug response in activated B cell-like diffuse large B cell lymphoma

​

This project focusses on the role of autophagy in regulating drug responsiveness in aggressive lymphomas. We showed that selective autophagy plays a key role in regulating the efficacy of Bruton’s tyrosine kinase (BTK) inhibitors in aggressive lymphomas. Now we will analyze the underlying molecular mechanisms to find ways to therapeutically exploit this pathway. We will (i) elucidate the exact autophagy pathway that influences drug response by a proteogenomic approach, (ii) investigate how relevant survival factors are targeted to autophagosomal degradation upon BTK inhibitor treatment, and (iii) identify synergistic drug combinations that act through this newly identified cell-toxic autophagy pathway.

​

 

​